Arcus Biosciences prices $250 million public offering at $18.25 per share
PositiveFinancial Markets

Arcus Biosciences has successfully priced its public offering at $18.25 per share, raising $250 million. This significant capital infusion is expected to bolster the company's research and development efforts, particularly in oncology. The positive response from investors highlights confidence in Arcus's innovative approach to cancer treatment, making this a pivotal moment for the company as it seeks to advance its pipeline and expand its market presence.
— Curated by the World Pulse Now AI Editorial System










